Schneider Elena K, Reyes-Ortega Felisa, Velkov Tony, Li Jian
Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria 3800, Australia.
Essays Biochem. 2017 Mar 3;61(1):115-125. doi: 10.1042/EBC20160058. Print 2017 Feb 28.
The emergence of antimicrobial resistance of Gram-negative pathogens has become a worldwide crisis. The status quo for combating resistance is to employ synergistic combinations of antibiotics. Faced with this fast-approaching post-antibiotic era, it is critical that we devise strategies to prolong and maximize the clinical efficacy of existing antibiotics. Unfortunately, reports of extremely drug-resistant (XDR) Gram-negative pathogens have become more common. Combining antibiotics such as polymyxin B or the broad-spectrum tetracycline and minocycline with various FDA-approved non-antibiotic drugs have emerged as a novel combination strategy against otherwise untreatable XDR pathogens. This review surveys the available literature on the potential benefits of employing antibiotic-non-antibiotic drug combination therapy. The apex of this review highlights the clinical utility of this novel therapeutic strategy for combating infections caused by 'superbugs'.
革兰氏阴性病原体的抗菌耐药性已成为一场全球危机。对抗耐药性的现状是使用抗生素的协同组合。面对这个迅速临近的后抗生素时代，我们制定策略来延长现有抗生素的临床疗效并使其最大化至关重要。不幸的是，超广谱耐药（XDR）革兰氏阴性病原体的报道变得越来越普遍。将多粘菌素B或广谱四环素及米诺环素等抗生素与各种美国食品药品监督管理局（FDA）批准的非抗生素药物联合使用，已成为一种针对原本无法治疗的XDR病原体的新型联合策略。本综述调查了关于采用抗生素 - 非抗生素联合疗法潜在益处的现有文献。本综述的重点突出了这种新型治疗策略在对抗“超级细菌”引起的感染方面的临床效用。
